Skip to content

Efficacy and safety of different dose ratios of cemented vancomycin in the treatment of osteoarticular infections: a multicentre, randomised, single-blind, parallel-controlled clinical trial

Efficacy and safety of different dose ratios of cemented vancomycin in the treatment of osteoarticular infections: a multicentre, randomised, single-blind, parallel-controlled clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400088674
Enrollment
Unknown
Registered
2024-08-23
Start date
2024-08-23
Completion date
Unknown
Last updated
2024-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bone and joint infections

Interventions

A:Bone cement: vancomycin is 40g:4g
B:Bone cement: vancomycin is 40g:8g
C:Bone cement: vancomycin is 40g:4g, along with some amount of calcium sulfate
D:Bone cement: vancomycin is 40g:8g, with a certain amount of calcium sulfate.

Sponsors

Shandong Public Health Clinical Centre
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (i) over 18 years old; (ii) patients diagnosed with osteoarthritis infection and needing surgical treatment; (iii) voluntary participation in the clinical trial; (iv) having complete medical history and clinical information, understanding and signing the informed consent form.

Exclusion criteria

Exclusion criteria: (i) under 18 years of age; (ii) not eligible for surgical indications; (iii) unclear diagnosis; (iv) suffering from other active infectious diseases; (v) received similar treatment regimens; (vi) patients who are allergic to bone cement vancomycin, calcium sulphate; (vii) pregnant women, breastfeeding females, and females planning to become pregnant.

Design outcomes

Primary

MeasureTime frame
cure rate;

Secondary

MeasureTime frame
Infection recurrence rate;Healing time;Harris Hip Score;Knee Society Knee Score;Pain assessment(VAS);Inflammatory cell count;Inflammatory biomarkers;

Countries

China

Contacts

Public ContactQiang Zhang

Shandong Public Health Clinical Centre

zq-9999@163.com+86 155 6265 9602

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026